SL THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 730 KRW | 0.00% |
|
-9.77% | +23.94% |
| 2022 | StemLab Inc. announced that it has received KRW 1.5000006 billion in funding | CI |
| 2022 | StemLab Inc. announced that it expects to receive KRW 1.5000006 billion in funding | CI |
More news
| 1 week | -9.77% | ||
| Current month | -1.08% | ||
| 1 month | -4.82% | ||
| 3 months | -18.44% | ||
| 6 months | -10.43% | ||
| Current year | +23.94% |
1 week
687.00
794.00
1 month
652.00846.00
Current year
503.001 000.00
1 year
376.002 000.00
3 years
376.008 010.00
5 years
376.009 283.33
10 years
376.0010 933.33
| Managers | Title | Age | Since |
|---|---|---|---|
Donghoon Oh
CEO | Chief Executive Officer | 61 | - |
Jong-Seong Choi
CEO | Chief Executive Officer | 60 | - |
Seung-Kwon Yoo
PSD | President | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joon Chung
BRD | Director/Board Member | 60 | - |
Jong-Seong Choi
CEO | Chief Executive Officer | 60 | - |
Donghoon Oh
CEO | Chief Executive Officer | 61 | - |
SL Therapeutics Inc, formerly Stem Lab Inc, is a Korea-based company principally engaged in the manufacture and sale of biopharmaceuticals. The Company is principally engaged in the development, research, manufacture and sale of biopharmaceuticals such as stem cell culture mediums, stem cell treatment as well as others.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +23.94% | 2.79M | |
| -1.62% | 89.22B | |
| +1.32% | 40.49B | |
| -15.59% | 32.79B | |
| +64.13% | 26.23B | |
| -22.06% | 14.52B | |
| -7.63% | 13.09B | |
| -44.07% | 11.6B | |
| -13.06% | 11.5B | |
| +4.94% | 8.82B |
- Stock Market
- Equities
- A258540 Stock
